Abu Dhabi’s sovereign investors Mubadala are set to acquire KELIX bio

Abu Dhabi sovereign investor ‘Mubadala Investment Company’ has recently entered into an agreement to acquire KELIX bio which is a specialty pharmaceutical business focused on delivering complex generics. KELIX bio has acquired manufacturing businesses in India, Egypt, Malta and Morocco and they have also commercialized a broad range of both oral and injectable formulations covering diverse therapy areas including diabetes, oncology, cardiology, and central nervous systems.

Prior to this acquisition KELIX bio was held by a consortium of investors including Development Partners International, British International Investment, the UK’s development finance institution and impact investor, and the European Bank for Reconstruction and Development. The transaction’s completion is subject to customary regulatory approvals.


Related Topics and Keywords


Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy